Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43974   clinical trials with a EudraCT protocol, of which   7312   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-002686-18
    Sponsor's Protocol Code Number:EP0162
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:
    Date on which this record was first entered in the EudraCT database:2021-08-12
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2021-002686-18
    A.3Full title of the trial
    A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to test the efficacy and safety of Staccato alprazolam in study participants 12 years of age and older with epilepsy
    A.4.1Sponsor's protocol code numberEP0162
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/220/2022
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUCB Biopharma SRL
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportUCB Biopharma SRL
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUCB BIOSCIENCES GmbH
    B.5.2Functional name of contact pointClin Trial Reg & Results Disclosure
    B.5.3 Address:
    B.5.3.1Street AddressAlfred-Nobel-Strasse 10
    B.5.3.2Town/ cityMonheim
    B.5.3.3Post code40789
    B.5.3.4CountryGermany
    B.5.6E-mailclinicaltrials@ucb.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameStaccato alprazolam
    D.3.2Product code UCB7538
    D.3.4Pharmaceutical form Inhalation powder
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNalprazolam
    D.3.9.3Other descriptive nameALPRAZOLAM
    D.3.9.4EV Substance CodeSUB05370MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Yes
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboInhalation powder
    D.8.4Route of administration of the placeboInhalation use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Treatment of stereotypical prolonged seizure
    E.1.1.1Medical condition in easily understood language
    Epilepsy
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10076333
    E.1.2Term Prolonged seizure
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Comparison of the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.
    E.2.2Secondary objectives of the trial
    - Comparison of the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 4 hours after IMP administration
    - Comparison of the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 6 hours after IMP administration
    - Comparison of the time from IMP administration to cessation of the treated seizure between Staccato alprazolam and placebo
    - Evaluate the pulmonary safety of a single dose of Staccato alprazolam compared with placebo
    - Comparison of the occurrence of subsequent seizure(s) up to 2 hours after IMP administration between Staccato alprazolam and placebo
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Participant must be ≥12 years of age at the Baseline/Randomization
    Visit
    - Participant must have a study caregiver ≥18 years of age at the
    Screening Visit; the study caregiver(s) must be a relative, partner,
    friend, or legally authorized representative (LAR) of the participant, or a person who provides daily care to the participant and has a significant personal relationship with the participant; the study caregiver(s) must be able to recognize and observe the participant's seizures
    - Participants with an established diagnosis of focal or generalized epilepsy or combined focal and generalized epilepsy with a documented history of stereotypical episodes of prolonged seizures that includes at least 1 of the following:
    a) Generalized seizure episodes starting with a flurry of absence
    seizures or myoclonic seizures with a minimum total duration of 5
    minutes
    b) Episodes of a focal seizure with a minimum duration of 3 minutes
    c) Episodes of a focal seizure or a flurry of myoclonic seizures for at least 90 seconds followed by a generalized/bilateral tonic-clonic seizure with a minimum total duration of 3 minutes
    - Prior to the Screening Visit, participant has experienced ≥4
    stereotypical episodes of prolonged seizures in the past 6 months, and the last 2 stereotypical episodes of prolonged seizures must have
    occurred within the 3 months prior to the Screening Visit
    - Participant has had a documented brain computerized tomography or magnetic resonance imaging review, performed after diagnosis of
    epilepsy and within the 5 years prior to the Screening Visit, that
    confirms the absence of a progressive neurological disorder
    - Participant is receiving a regimen of antiseizure medications (ASMs)
    that has been stable (ie, no addition or removal of ASM[s]; dose
    adjustments are permitted to ASM[s]; dose adjustments are not
    permitted for benzodiazepines) for 30 days prior to the Screening Visit
    - Male and female participants:
    a) A male participant must agree to use contraception during the
    Outpatient Treatment Period and for at least 7 days after investigational medicinal product (IMP) administration and refrain from donating sperm during this period
    b) A female participant is eligible to participate if she is not pregnant,
    not breastfeeding, and at least 1 of the following conditions applies:
    i) Not a woman of childbearing potential (WOCBP)
    OR
    ii) A WOCBP who agrees to follow the contraceptive guidance during
    the Outpatient Treatment Period and for at least 30 days after IMP
    administration
    - Participant is capable of giving signed informed consent (or giving
    assent, where required), which includes compliance with the
    requirements and restrictions listed in the informed consent form (ICF), the protocol, and the individualized participant management plan (iPMP). The informed consent form (ICF), or a specific assent form, where required, will be signed and dated by minors
    - The participant's study caregiver(s) must be capable of giving signed
    informed consent), which includes compliance with the requirements
    and restrictions listed in the ICF, the protocol, and the individualized
    participant management plan (iPMP)
    E.4Principal exclusion criteria
    - Participant has a current history of alcohol or drug use disorder, as
    defined in the Diagnostic and Statistical Manual of Mental Disorders 5,
    within the previous 1 year
    - Participant has a known hypersensitivity to any components of the IMP
    or comparable drugs (and/or an investigational device) as stated in this
    protocol or to albuterol (or similar bronchospasm rescue medication if
    needed to meet country-specific requirements)
    - Participant has a diagnosis of atrial fibrillation or mitral stenosis
    - Participant has a history of convulsive (generalized tonic-clonic) status
    epilepticus in the 8 weeks prior to the Screening Visit
    - Participant has a history or presence of known nonepileptic seizures
    which cannot be distinguished from qualifying epileptic seizures
    - Participant has a clinically significant known airway hypersensitivity (eg, bronchospasm to known allergens, such as pollen, animals, or food)
    and/or acute respiratory signs/symptoms (eg, shortness of breath,
    wheezing on lung auscultation)
    - Participant has a clinically significant chronic pulmonary disorder other
    than mild asthma (eg, chronic obstructive pulmonary disease, restrictive
    lung diseases [including idiopathic pulmonary fibrosis]) and/or recent
    history or presence of hemoptysis or pneumothorax
    - Participant has had a positive antigen test for SARS-CoV-2 and
    experienced moderate to severe signs/symptoms of respiratory distress
    necessitating hospitalization or outpatient treatment such as ambulatory
    oxygen, extensive treatment with inhaler medications, and/or oral
    medications for a duration of 4 weeks or more, unless full resolution
    occurred at least 6 months prior to Screening
    - Participant has experienced an upper respiratory tract infection within
    4 weeks or bronchitis/pneumonia within 3 months before the Screening
    Visit
    - Participant has a history or presence of acute narrow-angle glaucoma
    - Participant has a condition for which oral alprazolam is contraindicated
    (eg, myasthenia gravis, severe respiratory insufficiency, and sleep apnea
    syndrome)
    - Participant has a history or presence of long QT syndrome, a family
    history of sudden death due to long QT syndrome, or unexplained
    syncope
    - Chronic use of benzodiazepines for more than 3 days within a period of
    7 days will be allowed for approximately 30 % of study participants
    - Participant is taking any drug that is a strong CYP3A4 inhibitor,
    including azole antifungal agents (ketoconazole and itraconazole) and
    nefazodone
    - Participant is taking any opioids(eg, fentanyl, oxycodone, morphine) or
    sedative hypnotics on a chronic basis
    - Participant is taking nonselective beta blockers on a chronic basis
    - Participant is taking pharmacotherapy for an active major psychiatric
    disorder where major changes in regimen are needed or anticipated
    during the study
    - Participant has been treated with vagal nerve stimulation (VNS) for
    less than 6 months or VNS settings have changed within 30 days before
    the Screening Visit
    - Participant has a clinically significant laboratory abnormality that may
    increase the risk associated with study participation or may interfere
    with the interpretation of study results, according to the judgment of the
    Investigator
    - Participant has an oxygen saturation <95 % (or less than normal in
    regions of altitude >2500 meters) for greater than 30 seconds during
    the Screening Visit. In case of an out-of-range result, 1 repeat will be
    allowed. If the readings are out of range again, the study participant will
    be excluded
    - Participant has >2.0x upper limit of normal (ULN) of any of the
    following: alanine aminotransferase (ALT), aspartate aminotransferase
    (AST), alkaline phosphatase (ALP), or >1.0xULN total bilirubin (≥
    1.5xULN total bilirubin if known Gilbert's syndrome or >2.0xULN total
    bilirubin for liver impairment) -
    Participant has current unstable liver or biliary disease per Investigator
    assessment defined by the presence of ascites, encephalopathy,
    coagulopathy, hypoalbuminemia, esophageal or gastric varices,
    persistent jaundice, or cirrhosis
    - Participant has a QT interval corrected for heart rate (QTc) >450 msec
    (males), QTc interval >470 msec (females), or QTc interval >480 msec
    (participants with bundle branch block), PR interval ≥220msec, or any
    other clinically significant electrocardiogram (ECG) abnormality
    according to the Investigator i) The QTc is the QT interval corrected for
    heart rate according to Fridericia's formula (QTcF). It is either machine-read or manually over-read
    - Participant has a positive urine screen for drugs of abuse at the
    Screening Visit
    - Participant has a blood pressure (BP) or heart rate (HR) outside the
    following range after 5 minutes rest: systolic BP: 90 mmHg to 150
    mmHg; diastolicBP: 4 0mmHg to 95 mmHg; HR: 50 bpm to 100 bpm. In
    case of an out-of-range result, 1 repeat will be allowed. If the readings
    are out of range
    again, the study participant will be excluded


    E.5 End points
    E.5.1Primary end point(s)
    Treatment success for the treated seizure with no recurrence after 2 hours
    E.5.1.1Timepoint(s) of evaluation of this end point
    From start of IMP treatment through 2 hours
    E.5.2Secondary end point(s)
    1. Treatment success for treated seizure with no recurrence after 4 hours
    2. Treatment success for treated seizure with no recurrence after 6 hours
    3. Time from IMP administration to cessation of the treated seizure
    4. Frequency of respiratory treatment emergent adverse events (TEAEs)
    5. Number of subsequent seizure(s) up to 2 hours after IMP administration
    6. Time to first subsequent seizure up to 2 hours after IMP administration
    E.5.2.1Timepoint(s) of evaluation of this end point
    1: From start of IMP treatment through 4 hours
    2&3: From start of IMP treatment through 6 hours
    4: From start of IMP treatment up to the Safety Follow-up Visit (Week 19)
    5&6: From start of IMP treatment through 2 hours
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA43
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Ukraine
    Australia
    China
    Japan
    United Kingdom
    United States
    Bulgaria
    Czechia
    France
    Germany
    Hungary
    Italy
    Poland
    Spain
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days24
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days24
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 44
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 44
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 187
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 19
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Study population includes minors and cognitively impaired adults.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 98
    F.4.2.2In the whole clinical trial 250
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After completing the study, eligible study participants will be allowed to enroll in an open-label extension (OLE) study (EP0165).
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-12-02
    N.Ethics Committee Opinion of the trial application
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion
    P. End of Trial
    P.End of Trial Status
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA